With mandatory USP 665 and USP 1665 compliance arriving in May 2026, pharma and biopharma manufacturers must act now. Learn how Resolian’s E&L experts can help you build a compliant, risk-based testing programme.
Chiral method development is unpredictable and time-consuming. Resolian’s SFC workflow with Design of Experiments reduces workload while improving efficiency
How do you verify E&L screening readiness? Resolian developed a USP-based 15-compound system suitability standard ensuring UPLC-HRMS methods are fit for purpose.
What if your purification resin introduces impurities? Resolian’s multi-technique approach detects organic and inorganic PERLs from commercially available resins.
Can sustainable solvents match traditional E&L extraction performance? Resolian evaluates green alternatives that equal or exceed dichloromethane recovery.
Benzoyl peroxide can degrade to benzene during testing, creating false positives. Resolian’s antioxidant scavenger strategy prevents analytical artifacts.
Discover how Resolian’s green chemistry LC-HRMS method for extractables & leachables testing cut runtime by 37% and solvent use – without compromising sensitivity or quality.
Discover how Resolian’s platform SFC-UV method analyzes vitamin E across multiple formulations – reducing organic solvent use while meeting GMP requirements.
Discover how Resolian increased LC-MS sensitivity by 438% using Design of Experiments – achieving required detection limits without new equipment investment.
Resolian is committed to reducing its environmental impact wherever feasibly possible.
Recently the Extractables and Leachables team at the Fordham lab of Analytical Sciences aimed to implement and evaluate green chemistry principles.
Chief Scientific Officer
Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.
Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.
Chief Executive Officer
Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD.
Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.